Department of Cardiology, the First Affiliated Hospital of Wenzhou Medical University, China (L.S., S. Wang, S. Wu, L.X., Z.H., X.C., R.Z., L.J., W.H.).
The Key Lab of Cardiovascular Disease, Science and Technology of Wenzhou, China (L.S., S. Wang, S. Wu, L.X., Z.H., X.C., R.Z., L.J., W.H.).
Circ Arrhythm Electrophysiol. 2021 Feb;14(2):e009261. doi: 10.1161/CIRCEP.120.009261. Epub 2021 Jan 9.
Left bundle branch pacing (LBBP) is a novel pacing method and has been observed to have low and stable pacing thresholds in prior small short-term studies. The objective of this study was to evaluate the feasibility and safety of LBBP in a large consecutive diverse group of patients with long-term follow-up.
This study prospectively enrolled 632 consecutive pacemaker patients with attempted LBBP from April 2017 to July 2019. Pacing parameters, complications, ECG, and echocardiographic measurements were assessed at implant and during follow-up of 1, 6, 12, and 24 months.
LBBP was successful in 618/632 (97.8%) patients according to strict criteria for LBB capture. Mean follow-up time was 18.6±6.7 months. Two hundred thirty-one patients had follow-up over 2 years. LBB capture threshold at implant was 0.65±0.27 mV at 0.5 ms and 0.69±0.24 mV at 0.5 ms at 2-year follow-up. A significant decrease in QRS duration was observed in patients with left bundle branch block (167.22±18.99 versus 124.02±24.15 ms, <0.001). Postimplantation left ventricular ejection fraction improved in patients with QRS≥120 ms (48.82±17.78% versus 58.12±13.04%, <0.001). The number of patients with moderate and severe tricuspid regurgitation decreased at 1 year. Permanent right bundle branch injury occurred in 55 (8.9%) patients. LBB capture threshold increased to >3 V or loss of bundle capture in 6 patients (1%), 2 patients of them had a loss of conduction system capture. Two patients required lead revision due to dislodgement.
This large observational study suggests that LBBP is feasible with high success rates and low complication rates during long-term follow-up. Therefore, LBBP appears to be a reliable method for physiological pacing for patients with either a bradycardia or heart failure pacing indication.
左束支起搏(LBBP)是一种新的起搏方法,在先前的小型短期研究中观察到其起搏阈值较低且稳定。本研究的目的是在一个具有长期随访的大型连续多样化患者群体中评估 LBBP 的可行性和安全性。
本研究前瞻性纳入了 2017 年 4 月至 2019 年 7 月期间 632 例连续尝试行 LBBP 的起搏器患者。在植入时以及 1、6、12 和 24 个月的随访期间评估起搏参数、并发症、心电图和超声心动图测量值。
根据严格的 LBB 捕获标准,632 例患者中有 618 例(97.8%)起搏成功。平均随访时间为 18.6±6.7 个月。231 例患者的随访时间超过 2 年。植入时 LBB 捕获阈值为 0.5 ms 时为 0.65±0.27 mV,2 年随访时为 0.69±0.24 mV。左束支阻滞患者 QRS 时限明显缩短(167.22±18.99 比 124.02±24.15 ms,<0.001)。QRS 时间≥120 ms 的患者在植入后左心室射血分数提高(48.82±17.78%比 58.12±13.04%,<0.001)。1 年后,中重度三尖瓣反流患者数量减少。55 例(8.9%)患者发生永久性右束支损伤。6 例(1%)患者 LBB 捕获阈值增加至>3 V 或束支捕获丢失,其中 2 例患者丧失了传导系统捕获。2 例患者因脱位需要导线修订。
这项大型观察性研究表明,LBBP 在长期随访中具有较高的成功率和较低的并发症发生率,是一种可行的方法。因此,LBBP 似乎是一种可靠的生理性起搏方法,适用于心动过缓或心力衰竭起搏适应证的患者。